Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy of Isatuximab Combination Regimens in Patients with Relapsed and Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Thura Win Htut, Ei Moe Phyu, Myint Aung Win, Kyaw Zin Thein

Blood (2023) 142 (Supplement 1): 6676.

https://doi.org/10.1182/blood-2023-178252

Published: 2023

Journal Articles

Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections and Febrile Neutropenia in Patients with Multiple Myeloma Treated with Isatuximab

Thura Win Htut, Myint Aung Win, Myat Min Han, Kyaw Zin Thein

Blood (2023) 142 (Supplement 1): 7379.

https://doi.org/10.1182/blood-2023-178302

Published: 2023

Journal Articles

Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy

Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, Thein H. Oo

Blood (2022) 140 (Supplement 1): 10887–10888.

https://doi.org/10.1182/blood-2022-165629

Published: 2022

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy

Kyaw Zin Thein, Thura Win Htut, Myat Min Han, Yin Mon Myat, Myint Aung Win, Ei Moe Phyu, Thein H. Oo

Blood (2022) 140 (Supplement 1): 7997–7998.

https://doi.org/10.1182/blood-2022-165666

Published: 2022

Journal Articles

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Thura Win Htut, MBBS, MRCP, Sariya Wongsaengsak, MD, Myet Mon Zin, MD, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 798.

https://doi.org/10.1182/blood-2019-123177

Published: 2019

Journal Articles

Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Nimesh Adhikari, MD, Ei Moe Phyu, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 1873.

https://doi.org/10.1182/blood-2019-123164

Published: 2019

Journal Articles

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Kyaw Zin Thein, MDMBBS, Anita Sultan, MD, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Sanjay Awasthi, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD

Blood (2019) 134 (Supplement_1): 3485.

https://doi.org/10.1182/blood-2019-123145

Published: 2019

Journal Articles

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Anita Sultan, MD, Bradley J. Grant, JD, Donald P. Quick, MD, Chandler Graf, Sriman Swarup, MDMBBS, Sriman Swarup, MDMBBS, Jonathan Kopel, BS, Thura Win Htut, MBBS, MRCP, Somedeb Ball, MD, Ei Moe Phyu, MD, Myat Min Han, MD, Yin Mon Myat, MD, Nicholas D'Cunha, MD, Myint Aung Win, MDMBBS, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5480.

https://doi.org/10.1182/blood-2019-123231

Published: 2019

Journal Articles

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Jonathan Kopel, BS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Ei Moe Phyu, MD, Myint Aung Win, MDMBBS, Thura Win Htut, MBBS, MRCP, Ye Aung, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5489.

https://doi.org/10.1182/blood-2019-123179

Published: 2019

Journal Articles

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Thura Win Htut, MBBS, MRCP, Donald P. Quick, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Somedeb Ball, MD, Ei Moe Phyu, MD, Nyein Htway Yu, MBBS, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Nicholas D'Cunha, MD, Sanjay Awasthi, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5550.

https://doi.org/10.1182/blood-2019-123156

Published: 2019

Journal Articles

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors-Related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Bradley J. Grant, JD, Anita Sultan, MD, Nicholas D'Cunha, MD, Chandler Graf, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Thura Win Htut, MBBS, MRCP, Myat Min Han, MD, Yin Mon Myat, MD, Nimesh Adhikari, MD, Nyein Htway Yu, MBBS, MD, Donald P. Quick, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5877.

https://doi.org/10.1182/blood-2019-123531

Published: 2019

Journal Articles

Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma

Kyaw Zin Thein, MDMBBS, Thura Win Htut, MBBS, MRCP, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Somedeb Ball, MD, Ei Moe Phyu, MD, Aung M Tun, MD, Ramesh Pandey, MD, Myat Min Han, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD

Blood (2019) 134 (Supplement_1): 3158.

https://doi.org/10.1182/blood-2019-123131

Published: 2019

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Thura Win Htut, MBBS, MRCP, Aung M Tun, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Ei Moe Phyu, MD, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 4771.

https://doi.org/10.1182/blood-2019-123169

Published: 2019

NARROW

Efficacy of Isatuximab Combination Regimens in Patients with Relapsed and Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections and Febrile Neutropenia in Patients with Multiple Myeloma Treated with Isatuximab

Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy

Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors-Related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Efficacy of Upfront Daratumumab Combination Regimen in Patients with Newly Diagnosed Multiple Myeloma

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only